🧬 The Key Difference
Tirzepatide and retatrutide share two metabolic targets, but retatrutide adds a third receptor pathway.
-
Tirzepatide: GIP + GLP-1
-
Retatrutide: GIP + GLP-1 + Glucagon
🔥 Why Glucagon Is Interesting
Glucagon signaling can increase energy expenditure and influence how the body uses stored fuels. This creates an interesting research concept: combining reduced energy intake with a potential increase in energy expenditure.
🔬 What Human Research Shows
Human trials have reported substantial weight reduction with both approaches. However, results from separate clinical trials cannot determine which compound is more effective.
🧪 The Research Takeaway
Retatrutide adds glucagon receptor activity to GIP and GLP-1 signaling, giving researchers another pathway to investigate in energy expenditure and metabolism.
For research and educational purposes only. Not medical advice. Retatrutide is investigational and is not FDA approved.